Opinion

Video

Identifying the Right Patient Population for PSMA-PET Imaging

Author(s):

Brian Helfand, MD, PhD,Gordon A. Brown, DO

Experts on prostate cancer offer clinical insights on identifying the appropriate patients for PSMA-PET imaging.

Video content above is prompted by the following questions:

  • What are the current recommendations in terms of initial staging and evaluation and monitoring of prostate cancer and at recurrence? Are you adopting these recommendations in your practice?
    • Discuss the value of PSMA-PET imaging in patients with intermediate unfavorable and above disease.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Ruben Olivares, MD, answers a question during a Zoom video interview
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
1 expert in this video
1 expert in this video
Related Content
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke
The phase 1 study is set to begin later this year.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Real-world studies compare overall survival between ARPIs in mCSPC
June 19th 2025

Real-world studies compare overall survival between ARPIs in mCSPC

Mehmet Asim Bilen, MD Hannah Clarke
"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke
Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
© 2025 MJH Life Sciences

All rights reserved.